Featured Research

from universities, journals, and other organizations

Developing Cancer Treatments Directed At Critical Developmental Pathway

Date:
April 14, 2008
Source:
University of Pennsylvania School of Medicine
Summary:
Researchers discovered that the Notch signaling pathway, which determines the development of many cell types, and is also implicated in some cancers, is not universally essential for the maintenance of stem cells. This indicates that inhibitors of Notch may not affect bone marrow stem cells.

Researchers from the University of Pennsylvania School of Medicine and colleagues discovered that the Notch signaling pathway, which determines the development of many cell types, and is also implicated in some cancers, is not universally essential for the maintenance of stem cells. The findings appear this week in Cell Stem Cell, and indicate that inhibitors of Notch may not affect bone marrow stem cells.

Notch is one of a select set of proteins that influence the development of a wide variety of types of cells. Prior work has shown that increases in signals generated by Notch are important in certain human tumors, particularly some kinds of childhood leukemia, making Notch an attractive target for new cancer therapies. However, it has also been suggested that Notch is needed to maintain the stem cells in the bone marrow from which normal blood cells are formed, raising the concern that Notch inhibitors might destroy the normal bone marrow.

"This potential risk raised important questions about treating leukemia patients with Notch inhibitors," notes senior author Warren Pear, MD, PhD, Associate Professor of Pathology and Laboratory Medicine and the Abramson Family Cancer Research Institute.

Previous work from the Pear lab and others has shown that Notch signals are required for the proper development of lymphocytes. More importantly in terms of human disease, work done together with co-author Jon Aster's lab at Harvard over the last decade has shown that abnormal increases in Notch signaling cause T-cell acute lymphoblastic leukemias, which make up about 15-20 percent of childhood leukemias. Growth of these leukemias can be stopped in the laboratory by new kinds of Notch pathway inhibitors.

"We have several projects focused on the development of new leukemia therapies that are designed to inhibit Notch," notes Pear. "But it was important to know if this would have detrimental effects on bone marrow stem cells."

This new work from the Pear group and colleagues showed definitively that adult bone marrow stem cells do not require Notch signals, indicating that it should be possible to give these inhibitors to patients without fear of causing bone marrow failure.

This work was funded by the National Cancer Institute and the National Institute of Allergy and Infectious Diseases, the Leukemia and Lymphoma Society, and the Damon Runyon Foundation. Additional co-authors are lead author Ivan Maillard (University of Michigan) Avinish Bhandoola (Penn) and Freddy Radtke (Switzerland).


Story Source:

The above story is based on materials provided by University of Pennsylvania School of Medicine. Note: Materials may be edited for content and length.


Cite This Page:

University of Pennsylvania School of Medicine. "Developing Cancer Treatments Directed At Critical Developmental Pathway." ScienceDaily. ScienceDaily, 14 April 2008. <www.sciencedaily.com/releases/2008/04/080410131606.htm>.
University of Pennsylvania School of Medicine. (2008, April 14). Developing Cancer Treatments Directed At Critical Developmental Pathway. ScienceDaily. Retrieved October 20, 2014 from www.sciencedaily.com/releases/2008/04/080410131606.htm
University of Pennsylvania School of Medicine. "Developing Cancer Treatments Directed At Critical Developmental Pathway." ScienceDaily. www.sciencedaily.com/releases/2008/04/080410131606.htm (accessed October 20, 2014).

Share This



More Health & Medicine News

Monday, October 20, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

How Nigeria Beat Its Ebola Outbreak

How Nigeria Beat Its Ebola Outbreak

Newsy (Oct. 20, 2014) The World Health Organization has declared Nigeria free of Ebola. Health experts credit a bit of luck and the government's initial response. Video provided by Newsy
Powered by NewsLook.com
Another Study Suggests Viagra Is Good For The Heart

Another Study Suggests Viagra Is Good For The Heart

Newsy (Oct. 20, 2014) An ingredient in erectile-dysfunction medications such as Viagra could improve heart function. Perhaps not surprising, given Viagra's history. Video provided by Newsy
Powered by NewsLook.com
Ebola Worries End for Dozens on U.S. Watch Lists

Ebola Worries End for Dozens on U.S. Watch Lists

Reuters - US Online Video (Oct. 20, 2014) Forty-three people who had contact with Thomas Eric Duncan, the first person diagnosed with Ebola in the U.S., were cleared overnight of twice-daily monitoring after 21 days of showing no symptoms. Rough Cut (no reporter narration). Video provided by Reuters
Powered by NewsLook.com
Fauci: Ebola Protocols to Focus on Training

Fauci: Ebola Protocols to Focus on Training

AP (Oct. 20, 2014) Dr. Anthony Fauci, head of the National Institute of Allergy and Infectious Diseases, says he expects revised CDC protocols on Ebola to focus on training, observation and ensuring health care workers are more protected. (Oct. 20) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins